Synopsis
Synopsis
0
VMF
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 2 Amino 6 Propylaminotetrahydrobenzothiazole
2. 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
3. 2-amino-6-propylaminotetrahydrobenzothiazole
4. 4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine
5. 6,7-tetrahydro-n6-propyl-2,6-benzothiazolediamine Dihydrochloride Monohydrate
6. Dexpramipexole
7. Kns 760704
8. Kns-760704
9. Kns760704
10. Mirapex
11. Pramipexol
12. Pramipexol Dihydrobromide, (+-)-isomer
13. Pramipexol Dihydrochloride, (s)-isomer
14. Pramipexol, (+-)-isomer
15. Pramipexol, (r)-isomer
16. Pramipexole
17. Pramipexole Dihydrochloride
18. Pramipexole Dihydrochloride Anhydrous
19. Pramipexole Hydrochloride Monohydrate
20. Sifrol
21. Snd 919
22. Snd 919cl2x
23. Snd-919
24. Snd-919cl2x
25. Snd919cl2x
1. 191217-81-9
2. Mirapex
3. (s)-n6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Dihydrochloride Hydrate
4. Pramipexole 2hcl Monohydrate
5. Pramipexole Hydrochloride
6. Sifrol
7. Daquiran
8. Pramipexole Hydrochloride Hydrate
9. Pramipexole Teva
10. Pramipexole Accord
11. Snd919cl2y
12. Bi-sifrol
13. Pnu-98528e
14. 191712-81-9
15. (s)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole Dihydrochloride Monohydrate
16. Pramipexole Dihydrochloride [usan]
17. Chebi:51147
18. 3d867np06j
19. Oprymea
20. Pramipexole (dihydrochloride Hydrate)
21. Snd-919cl2y
22. (6s)-6-n-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;hydrate;dihydrochloride
23. Pramipexole Hydrochloride Hydrate (jan)
24. Pramipexole Dihydrochloride Anhydrous
25. Pramipexole Hydrochloride Hydrate [jan]
26. Pramipexole Hcl Hydrate
27. Unii-3d867np06j
28. Pramipexole Dihydrochloride Hydrate
29. Pramipexole Hydrate Dihydrochloride
30. Pnu 98528e
31. Mirapex (tn)
32. Pramipexole Dihydrochloride [usan:usp]
33. Dsstox_cid_24227
34. Dsstox_rid_80129
35. Dsstox_gsid_44227
36. Chembl3182733
37. Dtxsid1044227
38. Hy-b0410a
39. Pramipexole Dihydrochloride (usp)
40. Pramipexole Hydrochloride Monohydrate
41. Tox21_302316
42. Mfcd02183927
43. S2011
44. Akos015917338
45. Ccg-267486
46. Ks-1308
47. 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, Dihydrochloride, Monohydrate, (6s)-
48. Ncgc00255978-01
49. Pramipexole Hydrochloride [mart.]
50. 112gi013
51. Bp162212
52. Bp164285
53. Pramipexole Dihydrochloride [vandf]
54. Cas-191217-81-9
55. Cs-0013154
56. Sw197453-5
57. (s)-pramipexole 2hcl Monohydrate - Ep Grade
58. Pramipexole Dihydrochloride Monohydrate- Bio-x
59. D00559
60. T72003
61. Pramipexole Dihydrochloride [orange Book]
62. A846638
63. Pramipexole Dihydrochloride [usp Monograph]
64. J-012354
65. Pramipexole Dihydrochloride Monohydrate [mi]
66. Q27888021
67. Pramipexole Dihydrochloride Monohydrate [ema Epar]
68. Pramipexole Dihydrochloride Monohydrate [usp-rs]
69. Pramipexole Dihydrochloride Monohydrate [who-dd]
70. Pramipexole Dihydrochloride Monohydrate [ep Monograph]
71. (6s)-n(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Dihydrochloride Hydrate
72. (s)-2-amino-4,5,6,7-tetrahydro-6(propylamino)benzothiazole Dihydrochloride Monohydrate
73. (s)-n6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine 2hcl Hydrate
74. (s)-n6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diaminedihydrochloridehydrate
Molecular Weight | 302.3 g/mol |
---|---|
Molecular Formula | C10H21Cl2N3OS |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 301.0782389 g/mol |
Monoisotopic Mass | 301.0782389 g/mol |
Topological Polar Surface Area | 80.2 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 188 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 4 |
1 of 4 | |
---|---|
Drug Name | Mirapex |
PubMed Health | Pramipexole (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | MIRAPEX tablets contain pramipexole, a nonergot dopamine agonist. The chemical name of pramipexole dihydrochloride is (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate. Its empirical formula is C10 H17 N3 S 2... |
Active Ingredient | Pramipexole dihydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.5mg; 1mg; 0.25mg; 0.75mg; 1.5mg; 0.125mg |
Market Status | Prescription |
Company | Boehringer Ingelheim |
2 of 4 | |
---|---|
Drug Name | Pramipexole dihydrochloride |
Drug Label | MIRAPEX tablets contain pramipexole, a nonergot dopamine agonist. The chemical name of pramipexole dihydrochloride is (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate. Its empirical formula is C10 H17 N3 S 2... |
Active Ingredient | Pramipexole dihydrochloride |
Dosage Form | Tablet, extended release; Tablet |
Route | Oral |
Strength | 0.5mg; 1mg; 0.25mg; 0.75mg; 3.75mg; 1.5mg; 4.5mg; 2.25mg; 0.375mg; 3mg; 0.125mg |
Market Status | Prescription |
Company | Anchen Pharms; Alembic; Breckenridge Pharm; Apotex; Aurobindo Pharma; Sun Pharm Inds; Torrent Pharms; Sandoz; Actavis Grp Ptc; Watson Labs; Strides Pharma; Glenmark Generics; Teva Pharms; Macleods Pharms; Zydus Pharms Usa; Mylan; Barr |
3 of 4 | |
---|---|
Drug Name | Mirapex |
PubMed Health | Pramipexole (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | MIRAPEX tablets contain pramipexole, a nonergot dopamine agonist. The chemical name of pramipexole dihydrochloride is (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate. Its empirical formula is C10 H17 N3 S 2... |
Active Ingredient | Pramipexole dihydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 0.5mg; 1mg; 0.25mg; 0.75mg; 1.5mg; 0.125mg |
Market Status | Prescription |
Company | Boehringer Ingelheim |
4 of 4 | |
---|---|
Drug Name | Pramipexole dihydrochloride |
Drug Label | MIRAPEX tablets contain pramipexole, a nonergot dopamine agonist. The chemical name of pramipexole dihydrochloride is (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate. Its empirical formula is C10 H17 N3 S 2... |
Active Ingredient | Pramipexole dihydrochloride |
Dosage Form | Tablet, extended release; Tablet |
Route | Oral |
Strength | 0.5mg; 1mg; 0.25mg; 0.75mg; 3.75mg; 1.5mg; 4.5mg; 2.25mg; 0.375mg; 3mg; 0.125mg |
Market Status | Prescription |
Company | Anchen Pharms; Alembic; Breckenridge Pharm; Apotex; Aurobindo Pharma; Sun Pharm Inds; Torrent Pharms; Sandoz; Actavis Grp Ptc; Watson Labs; Strides Pharma; Glenmark Generics; Teva Pharms; Macleods Pharms; Zydus Pharms Usa; Mylan; Barr |
Sifrol is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, though to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).
Sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0. 54 mg of base (0. 75 mg of salt).
Mirapexin is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).
Mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0. 54 mg of base (0. 75 mg of salt).
Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).
Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0. 54 mg of base (0. 75 mg of salt) (see section 4. 2).
Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).
Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0. 54 mg of base (0. 75 mg of salt) (see section 4. 2).
Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).
DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i. e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).
Combined vocal and multiple motor tic disorder (de la Tourette), Restless Legs Syndrome
Combined vocal and multiple motor tic disorder (de la Tourette), Restless Legs Syndrome
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Antioxidants
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
N04BC05
N04BC05
N04BC05
N04BC05
N04BC05
N04BC05
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
51
PharmaCompass offers a list of Pramipexole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pramipexole manufacturer or Pramipexole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pramipexole manufacturer or Pramipexole supplier.
PharmaCompass also assists you with knowing the Pramipexole API Price utilized in the formulation of products. Pramipexole API Price is not always fixed or binding as the Pramipexole Price is obtained through a variety of data sources. The Pramipexole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pramipexole Dihydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pramipexole Dihydrochloride, including repackagers and relabelers. The FDA regulates Pramipexole Dihydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pramipexole Dihydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pramipexole Dihydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pramipexole Dihydrochloride supplier is an individual or a company that provides Pramipexole Dihydrochloride active pharmaceutical ingredient (API) or Pramipexole Dihydrochloride finished formulations upon request. The Pramipexole Dihydrochloride suppliers may include Pramipexole Dihydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Pramipexole Dihydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pramipexole Dihydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Pramipexole Dihydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Pramipexole Dihydrochloride DMFs exist exist since differing nations have different regulations, such as Pramipexole Dihydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pramipexole Dihydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Pramipexole Dihydrochloride USDMF includes data on Pramipexole Dihydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pramipexole Dihydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pramipexole Dihydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pramipexole Dihydrochloride Drug Master File in Japan (Pramipexole Dihydrochloride JDMF) empowers Pramipexole Dihydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pramipexole Dihydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Pramipexole Dihydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pramipexole Dihydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pramipexole Dihydrochloride Drug Master File in Korea (Pramipexole Dihydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pramipexole Dihydrochloride. The MFDS reviews the Pramipexole Dihydrochloride KDMF as part of the drug registration process and uses the information provided in the Pramipexole Dihydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pramipexole Dihydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pramipexole Dihydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pramipexole Dihydrochloride suppliers with KDMF on PharmaCompass.
A Pramipexole Dihydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Pramipexole Dihydrochloride Certificate of Suitability (COS). The purpose of a Pramipexole Dihydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Pramipexole Dihydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Pramipexole Dihydrochloride to their clients by showing that a Pramipexole Dihydrochloride CEP has been issued for it. The manufacturer submits a Pramipexole Dihydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Pramipexole Dihydrochloride CEP holder for the record. Additionally, the data presented in the Pramipexole Dihydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Pramipexole Dihydrochloride DMF.
A Pramipexole Dihydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Pramipexole Dihydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Pramipexole Dihydrochloride suppliers with CEP (COS) on PharmaCompass.
A Pramipexole Dihydrochloride written confirmation (Pramipexole Dihydrochloride WC) is an official document issued by a regulatory agency to a Pramipexole Dihydrochloride manufacturer, verifying that the manufacturing facility of a Pramipexole Dihydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pramipexole Dihydrochloride APIs or Pramipexole Dihydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Pramipexole Dihydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Pramipexole Dihydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pramipexole Dihydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pramipexole Dihydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pramipexole Dihydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pramipexole Dihydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pramipexole Dihydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pramipexole Dihydrochloride suppliers with NDC on PharmaCompass.
Pramipexole Dihydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pramipexole Dihydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pramipexole Dihydrochloride GMP manufacturer or Pramipexole Dihydrochloride GMP API supplier for your needs.
A Pramipexole Dihydrochloride CoA (Certificate of Analysis) is a formal document that attests to Pramipexole Dihydrochloride's compliance with Pramipexole Dihydrochloride specifications and serves as a tool for batch-level quality control.
Pramipexole Dihydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Pramipexole Dihydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pramipexole Dihydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Pramipexole Dihydrochloride EP), Pramipexole Dihydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pramipexole Dihydrochloride USP).